# DBV Technologies S.A.: overview DBVT · Nasdaq · CIK 1613780 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dbvt.md) · [Financials](/companies/dbvt/financials.md) · [Filings](/companies/dbvt/filings.md) · [Insiders](/companies/dbvt/insiders.md) Latest reported revenue: [$1.6m](/filings/0001628280-26-067930.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-067930). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.5 d](/filings/0001628280-26-021504.md) | [0.8](/filings/0001628280-26-028929.md) | [1.5](/filings/0001628280-26-048453.md) | [2.8](/filings/0001628280-26-067930.md) | [0.6 d](/filings/0001628280-26-021504.md) | [0.9](/filings/0001628280-26-028929.md) | [0.7](/filings/0001628280-26-048453.md) | [1.6](/filings/0001628280-26-067930.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4669.5%) d](/filings/0001628280-26-021504.md) | [(3325.0%)](/filings/0001628280-26-028929.md) | [(2740.0%)](/filings/0001628280-26-048453.md) | [(1225.0%)](/filings/0001628280-26-067930.md) | [(7084.3%) d](/filings/0001628280-26-021504.md) | [(5322.2%)](/filings/0001628280-26-028929.md) | [(7228.6%)](/filings/0001628280-26-048453.md) | [(4050.0%)](/filings/0001628280-26-067930.md) | | Net margin | % | [(4503.9%) d](/filings/0001628280-26-021504.md) | [(3387.5%)](/filings/0001628280-26-067930.md) | [(2793.3%)](/filings/0001628280-26-067930.md) | [(1185.7%)](/filings/0001628280-26-067930.md) | [(7051.4%) d](/filings/0001628280-26-021504.md) | [(5288.9%)](/filings/0001628280-26-067930.md) | [(7200.0%)](/filings/0001628280-26-067930.md) | [(4031.3%)](/filings/0001628280-26-067930.md) | | Diluted EPS | $ per share | not reported | [(0.26)](/filings/0001628280-26-028929.md) | [(0.31)](/filings/0001628280-26-048453.md) | [(0.24)](/filings/0001628280-26-067930.md) | not reported | [(0.11)](/filings/0001628280-26-028929.md) | [(0.12)](/filings/0001628280-26-048453.md) | [(0.14)](/filings/0001628280-26-067930.md) | | Free cash flow | $m | [(12.4) d](/filings/0001628280-26-021504.md) | [(19.7)](/filings/0001628280-26-028929.md) | [(33.9) d](/filings/0001628280-26-048453.md) | [(32.6) d](/filings/0001628280-26-067930.md) | [(35.5) d](/filings/0001628280-26-021504.md) | [(49.5)](/filings/0001628280-26-028929.md) | [(53.0) d](/filings/0001628280-26-048453.md) | [(53.7) d](/filings/0001628280-26-067930.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.7](/filings/0001193125-23-058309.md) | [4.8](/filings/0001193125-24-062357.md) | [15.7](/filings/0001613780-25-000006.md) | [4.2](/filings/0001628280-26-021504.md) | [5.6](/filings/0001628280-26-021504.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1727.6%)](/filings/0001193125-23-058309.md) | [(1994.9%)](/filings/0001193125-24-062357.md) | [(486.0%)](/filings/0001613780-25-000006.md) | [(2808.7%)](/filings/0001628280-26-021504.md) | [(2609.2%)](/filings/0001628280-26-021504.md) | | Net margin | % | [(1713.5%)](/filings/0001193125-23-058309.md) | [1987.5%](/filings/0001193125-25-100826.md) | [462.3%](/filings/0001193125-25-100826.md) | [(2744.4%)](/filings/0001628280-26-021504.md) | [(2607.3%)](/filings/0001628280-26-021504.md) | | Diluted EPS | $ per share | [(1.78)](/filings/0001193125-23-058309.md) | [(1.24)](/filings/0001193125-24-062357.md) | [(0.76)](/filings/0001613780-25-000006.md) | [(1.17)](/filings/0001628280-26-021504.md) | [(1.05)](/filings/0001628280-26-021504.md) | | Free cash flow | $m | [(109)](/filings/0001193125-23-058309.md) | [(56.4)](/filings/0001193125-24-062357.md) | [(80.3)](/filings/0001613780-25-000006.md) | [(107)](/filings/0001628280-26-021504.md) | [(122)](/filings/0001628280-26-021504.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dbvt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $60.1m | 3,666,284 | | Reduced −1,547,077 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $30.5m | 1,857,362 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $30.3m | 1,844,758 | | Reduced −822,811 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $27.1m | 1,653,350 | | Added +688,959 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $24.0m | 1,461,425 | | Unchanged | | [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $22.5m | 1,372,851 | | Reduced −846,535 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $21.5m | 1,313,439 | | Added +1,233,902 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $15.7m | 954,908 | | Added +808,792 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $15.0m | 915,000 | | New +915,000 | | [Patient Square Capital LP](/funds/1819257.md) | 2026-06-30 | $14.9m | 909,474 | | Added +215,940 | ## Recent filings [All 564 filings](/companies/dbvt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 17:24 ET | [8-K](/filings/0001193125-26-436411.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436411 | | 2026-10-28 | 16:54 ET | [10-Q](/filings/0001628280-26-067930.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067930 | | 2026-09-30 | 21:18 ET | [8-K](/filings/0001193125-26-408052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-408052 | | 2026-07-16 | 17:02 ET | [8-K](/filings/0001193125-26-306222.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-306222 | | 2026-07-16 | 16:08 ET | [10-Q](/filings/0001628280-26-048453.md) | Quarterly report, period 2026-06-30 | 0001628280-26-048453 | | 2026-06-29 | 16:28 ET | [8-K](/filings/0001193125-26-288533.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-288533 | | 2026-06-05 | 16:01 ET | [8-K](/filings/0001193125-26-259488.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-259488 | | 2026-06-03 | 16:05 ET | [8-K](/filings/0001193125-26-255414.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-255414 | | 2026-05-11 | 06:55 ET | [DEF 14A](/filings/0001193125-26-215657.md) | Proxy statement, period 2026-06-03 | 0001193125-26-215657 | | 2026-05-05 | 16:01 ET | [8-K](/filings/0001193125-26-206315.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-206315 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-021504.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/47d9e02b-ff07-43e6-9450-b0f9eb3e51fb) ## About the filer - CIK: 1613780 - Tickers: DBVT, DBVTF - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: I0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 05:16 ET. No prices; not investment advice.